Background. Infections are a major cause of morbidity and mortality in kidney allograft recipients. In this post hoc analysis of a randomized clinical trial which tested the effect of denosumab on bone mineral density, we assessed the impact of this drug on the incidence and severity of infections in the first year after kidney transplantation. Methods. In this clinical trial, we randomized 90 de novo kidney transplant recipients shortly after transplantation to either denosumab on top of standard treatment (calcium and vitamin D) (n = 46), or to standard treatment alone (n = 44). Among all adverse events, we analyzed all infections that occurred within the first year after transplantation, and compared their incidence and severity in both groups. Results. Overall, we identified more infections (n = 146) in the denosumab group than in the control group (n = 99). The most common infections were urinary tract infection (cystitis) (34.9% vs 25.2%), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14.1%), polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex infections (5.5% vs 4.0%). Episodes of urinary tract infection (cystitis) occurred more often in the denosumab than in the control group (51 vs 25 episodes in 24 vs 11 patients, P = 0.008), whereas episodes of transplant pyelonephritis or urosepsis were not more frequent (3 vs 5 episodes). Conclusions. This post hoc analysis reveals that treatment with denosumab to prevent bone loss in first-year kidney transplant recipients was associated with more frequent episodes of urinary tract infections, whereas other infections occurred with similar frequency in both treatment groups.
(Transplantation 2017;101: 2139-2145)
A major cause of morbidity and mortality in kidney transplant recipients are infections. 1 The risk of infection is influenced by a variety of factors including immunosuppressive therapy, treatment of rejection episodes, reactivation of a previous latent infection, presence of indwelling catheters, nutritional status, and uncontrolled glycemia in patients with diabetes mellitus. [2] [3] [4] The impact of infections can be reduced by careful pretransplant screening of recipients and donors, vaccinations, posttransplant infection prophylaxis, and appropriate dosing of the immunosuppressive treatment. 2, 5 The incidence and the type of infections that occur after transplantation typically follow a characteristic pattern with regard to time after transplantation. 6 However, the introduction of novel therapeutic agents, particularly drugs which affect the immune system or the host defense, may lead to unexpected or novel infectious complications. Examples are the increasing incidence of BK virus nephropathy 7, 8 that can be attributed at least in part to the introduction of immunosuppressive drugs, such as tacrolimus and mycophenolate, or the higher risk for Epstein-Barr virus-associated lymphomas in patients treated with the novel immunosuppressant belatacept. 9, 10 Kidney transplant recipients often have osteopenia or osteoporosis which leads to an increased risk for fractures. 11 Therapeutic options to improve the loss of bone mass include supplementation with calcium and vitamin D and its analogues, 12, 13 and treatment with bisphosphonates. [14] [15] [16] [17] In a randomized clinical trial we have recently shown that denosumab-a fully human monoclonal antibody against receptor activator of nuclear factor κB ligand (RANKL)-effectively increased bone mineral density when given during the first year after kidney transplantation. 18 In that trial, we noticed that denosumab unexpectedly increased the incidence of urinary tract infections. We therefore sought to analyze in detail all infectious episodes that occurred during this clinical trial, and to obtain more information regarding the type and course of the infectious episodes.
MATERIALS AND METHODS

Study Design
The trial design has previously been described in detail (NCT01377467). 18 In brief, this academic study was a 1-year prospective single-center, randomized, parallel-group, open-label clinical trial in 90 de novo kidney transplant recipients. Patients were randomized to receive subcutaneous injections of 60 mg denosumab at baseline and after 6 months (n = 46) or no treatment (n = 44). All patients received calcium (1000 mg) and vitamin D (800 IU or more) supplementation as a standard treatment. All patients were followed up in the same institution in the first year after transplantation. Study visits were performed at baseline and months 0.5, 1, 2, 3, 6, and 12. All clinical and routine laboratory values and all adverse events (AEs) including infections were captured with a secured Web-based case report form (secuTrial; interActive Systems, Berlin, Germany).
All infectious episodes were carefully reviewed to document their type, severity, and duration. In particular, all microbiology, virology, and serology results were reviewed in all patients to classify the infections.
Urinary tract infection (cystitis) was defined as an episode of local urinary symptoms such as dysuria, frequency or urgency in combination with the presence of greater than 10 5 cfu/mL on urine culture with or without leukocyturia. Episodes of urinary tract infection with negative urine culture were also counted if clinically suggestive and empirically treated with antibiotics. The severity of urinary tract infection was defined according to the Common Terminology Criteria for AEs Version 4.0.
Transplant Procedure and Posttransplant Management
Among all 90 kidney transplants, 44 (48.9%) were from deceased donors and 46 (51.1%) from living donors. Preemptive transplantation was performed in 17 patients (18.9%) and repeat transplantation in 14 patients (15.6%). During transplantation, a pigtail catheter was inserted routinely to stent the transplant ureter, and a Foley catheter to drain the bladder. The Foley catheter was removed 4 to 6 days after surgery and the pigtail catheter 6 weeks posttransplantation.
Patients received induction treatment with basiliximab (68.9%) or antithymocyte globulin (30.0%), together with triple immunosuppression therapy which included a calcineurin inhibitor (70% tacrolimus, 30% cyclosporine), mycophenolate, and corticosteroids. Corticosteroids were tapered and successfully removed from 3 patients (3.3%) after 6 months, and from another 42 patients (46.7%) after 12 months.
All patients received a daily chemoprophylaxis with trimethoprim (80 mg) and sulfamethoxazole (400 mg) for Pneumocystis jirovecii and urinary tract infections in the first 6 months posttransplant. Cytomegalovirus (CMV) was approached with a preemptive strategy. Thus, CMV prophylaxis with daily valganciclovir (900 mg, adapted for renal function) for the first 3 months was only prescribed to high-risk (D+/R−) and intermediate risk patients (D+/R+; D−/R+) if they received antithymocyte globulin induction treatment.
Statistical Analysis
Categorical data were analyzed with the χ 2 test or Fisher exact test to check for independence of 2 variables. For the analysis of stratified categorical data, the Mantel-Haenszel test was used. The exact Wilcoxon rank sum test was used to compare for differences in ordinal or interval scaled, not normally distributed variables.
RESULTS
The study population included 90 kidney transplant recipients. Patients were randomized after a mean (SD) of 15.7 (6.4) days after transplantation to denosumab treatment (n = 46) at a dose of 60 mg subcutaneously at baseline and at 6 months or no treatment (n = 44). Two patients did not receive denosumab and another 2 patients received only the baseline injection of denosumab.
The baseline patient characteristics are shown in Table 1 . The 2 study groups were generally well balanced, except that the denosumab group had more men and more living donor transplants. Both study groups were treated with similar immunosuppression. The CMV risk profile was similar in both groups.
During the 12-month study period, we recorded a total of 349 AEs in the denosumab group (7.6 AE per patient) and 273 AE in the control group (6.2 AE per patient), of which 146 (41.8%) and 99 (36.3%), respectively, were infections. The number of infections per patient tended to be higher in the denosumab than in the control group (median, 3 vs 2 infections; P = 0.068), but the number of patients with any infection was not different in the 2 treatment groups (41 vs 37; P = 0.482). Table 2 shows that the most common infections were urinary tract infections (cystitis) (31.0%), CMV viremia (20.4%), flu-like syndrome (12.6%), polyoma (BK) viremia (9.3%), and herpes simplex infections (4.9%). Of importance, episodes of urinary tract infection occurred in more patients in the denosumab than in the control group (51 vs 25 episodes), whereas the number of episodes with CMV viremia (26 vs 24), flu-like syndrome (17 vs 14) , polyoma (BK) viremia (12 vs 11) and herpes simplex infection (8 vs 4) did not differ.
We noticed 5 acute rejection episodes in 5 patients in the denosumab group and 4 acute rejection episodes in 3 patients in the control group. The cumulative amount of corticosteroids over the 12-month study period was similar, amounting to 3.760 ± 1.445 g in the denosumab and 3.974 ± 1.727 g in the control group.
Urinary Tract Infections (Cystitis) and Pyelonephritis/Urosepsis
Episodes of urinary tract infection (cystitis) occurred in more patients in the denosumab than in the control group (24 vs 11 patients; odds ratio, 3.3; 95% confidence interval, 1.3-8.0; P = 0.008), whereas transplant pyelonephritis and urosepsis showed no difference in the 2 groups (3 vs 5 patients, P = 0.480). Clinically, the 51 episodes of urinary tract infection (cystitis) in the denosumab group were of mild (3.9%), moderate (76.5%), or severe (19.6%) degree. The 25 episodes in the control group were of moderate (56.0%) or severe (44.0%) degree. Thus, the fraction of severe episodes of urinary tract infections were higher in the control than in the denosumab group (P = 0.025). Figure 1 displays the cumulative incidence of the urinary tract infections in both groups. In the denosumab group there were 4/51 urinary tract infections and in the control group 0 of 25 infection that occurred early in the first 4 to 6 days after transplantation while the Foley catheter was in place. In the denosumab group, 20 of the 51 urinary tract infections and 6 of the 25 infections in the control group occurred in the first 6 weeks after transplantation while the ureteral stent was in place. In the denosumab group, 18 of the 51 urinary tract infections and 7 of the 25 infections in the control group occurred between 6 and 12 months after transplantation, that is, at the time when antibiotic prophylaxis had been stopped. Overall, two thirds of the urinary tract infections occurred in the first 6 months after transplantation and did not coincide with the removal of the pigtail catheter 6 weeks posttransplant, or follow up the application of denosumab at baseline and after 6 months, or follow up the removal of the antibiotic prophylaxis. In addition, there was no difference in the duration of the urinary drainage with the Foley catheter or the ureteral stents in both groups.
Women tended to be affected by urinary tract infections more often than men (16/33 vs 19/57) (P = 0.155). Because sex was not equally distributed between the treatment groups, the odds ratio of 3.3 for urinary tract infections under denosumab treatment raised to 4.8 (95% confidence interval, 1.7-13.5) when controlling for sex. Other parameters did not seem to have an influence on the frequency of urinary tract infections. Thus, neither the type of donation (living vs deceased; P = 0.361) nor the type of induction therapy (ATG vs basiliximab; P = 0.424) were associated with the occurrence of urinary tract infections.
The urine cultures were positive in all 25 episodes of urinary tract infection in the control group (100%), whereas only 42 of 51 cultures were positive in the denosumab group (82%), despite a clear clinical diagnosis of urinary tract infection. The spectrum of urine bacteria was similar in the denosumab and control group ( Table 3 ). The most frequent bacteria included Escherichia coli (n = 23), Klebsiella pneumonia (n = 12), and Enterococcus faecalis (n = 9). E. coli (17/51 vs 6/25 urinary tract infections) and E. faecalis (8/51 vs 1/25 urinary tract infections) occurred more frequently in the denosumab than in the control group. The pathogen for all 8 episodes of pyelonephritis was E. coli.
Urinary tract infections were treated with oral (n = 55) or intravenous antibiotics (n = 21). Oral antibiotics were prescribed for 41 (80.4%) infections in the denosumab group and for 14 infections in the control group (56.0%). In the denosumab group, 10 (19.6%) infections were treated with intravenous therapy versus 11 (44.0%) infections in the control group.
CMV Viremia
The details regarding CMV viremia are shown in Table 4 . CMV viremia occurred with similar frequency in both groups (20 vs 18 patients, P = 0.805). The median time to CMV viremia occurrence after transplantation was similar in both groups. In each group, 5 primary infections occurred after stopping the CMV prophylaxis with valganciclovir. The distribution of CMV viremia was significantly different for low-risk, intermediate-risk, and high-risk constellation (P = 0.003), with most viremias occurring in the intermediate-risk and high-risk constellations. CMV disease occurred in none of the patients in the denosumab group and in 1 patient in the control group. This patient developed diarrhea, and the histologic specimen from the colonoscopy confirmed the diagnosis of CMV colitis. Oral valganciclovir was prescribed to 23 viremias in the denosumab group and 11 viremias in the control group. Intravenous ganciclovir was used in 1 case in the denosumab group and 6 cases in the control group. Two and 7 cases with intermediate risk constellation received no treatment due to a very low virus replication (<2000 copies/mL). In summary, denosumab did not appear to alter the incidence, severity, and duration of CMV infection.
Flu-Like Syndromes
Flu-like syndromes occurred in 12 patients in the denosumab group and 13 patients in the control group (P = 0.714). A total of 24 of the infections occurred between October and April and 7 infections between May and September, corresponding to the seasonal variation.
Polyoma (BK) Viremia
The details regarding BK viremia are shown in Table 4 . The number of patients with BK viremia was not different between the 2 groups, whereas the median time to BK viremia after transplantation occurred significantly earlier in the control group (P = 0.049). One case of biopsy-proven BK virus nephropathy occurred in the denosumab group and none in the control group. In the denosumab group, 5 infections occurred in patients with ATG induction and 6 infections with basiliximab induction. In the control group, 4 infections occurred in patients treated with ATG and 7 infections when treated with basiliximab. In summary, denosumab did not appear to significantly alter the incidence, severity and duration of BK virus infection.
Herpes Simplex Type 1 and Herpes Zoster Infections
Herpes simplex type 1 (HSV 1) infections occurred with similar frequency in the denosumab and control groups (5 vs 4, P = 0.714). One case of a disseminated HSV 1 infection occurred in the denosumab group and 1 case of herpes oesophagitis (HSV 1) occurred in the control group. Both cases were successfully treated with oral valaciclovir for 10 days. The other cases were classical herpes labialis infections.
One patient in the denosumab group and 2 patients in the control group received oral valaciclovir as primary therapy for herpes labialis and 6 patients in the denosumab group and none in the control group received local therapy with topical acyclovir. One patient in the control group received neither valaciclovir nor acyclovir.
There were 3 cases of herpes zoster in the denosumab group and none in the control group, suggesting that denosumab could promote these infections. None of the FIGURE 1. Cumulative incidence of lower urinary tract infections in the first year after transplantation in both study groups.
cases was a disseminated infection. The localization along the dermatomas was in the face, thoracic, and on the leg. All 3 cases were treated with oral valaciclovir for 10 days and none of the patient had a relapse.
Other Relevant Infections
Wound infections (4 vs 0) as well as cutaneous infections (4 vs 0) were seen more often in the denosumab group than in the control group. Thus, although the number of wound and cutaneous infections was small, it appears that denosumab may promote these infections.
DISCUSSION
Denosumab is a new and first-in-class antiosteoporotic drug which is highly effective in preventing vertebral and nonvertebral fractures in postmenopausal women with osteoporosis 19 and has shown superior efficacy when compared with bisphosphonates in this patient population. 20 Although generally well tolerated, infections involving the gastrointestinal tract, the renal and urinary system and the skin were shown to occur slightly more often in patients treated with denosumab compared with placebo. [21] [22] [23] [24] Whether kidney transplant recipients under immunosuppressive treatment are at higher risk for infection when treated with denosumab has not been studied yet. 6, 25 The post hoc analysis of our study revealed a higher number of infections in denosumab-treated renal transplant recipients compared with patients in the control group. In particular, denosumab treatment led to a doubling of the number of urinary tract infections (cystitis), whereas other types of infections, particularly opportunistic infections with CMVand BK virus were not more common with denosumab treatment. Such a high incidence of urinary tract infections was not seen in postmenopausal women treated with denosumab, 19 suggesting that immunosuppressed de novo renal transplant recipients are more vulnerable to this type of infection.
The mechanisms which lead to such a high number of urinary tract infections are probably multifactorial. It has been suggested that the inhibition of the RANK/RANKL pathway with denosumab could decrease the resistance to microbial organisms by unknown mechanisms. 26, 27 Renal transplant patients are known to be particularly susceptible to urinary 2 -vitamin D progressively increased in both groups to similar levels at 12 months, suggesting that the difference in urinary tract infections in the 2 groups cannot be explained with the immunomodulatory activities of vitamin D. 18 Furthermore, in the setting of strong triple immunosuppression in the first months after transplantation, denosumab may contribute to a further increase in the incidence of these infections.
Fortunately, the urinary tract infections in both groups represented mostly benign episodes of cystitis which could easily be managed with antibiotics, and transplant pyelonephritis or urosepsis were not more common in the denosumab group. Furthermore, the severity and duration of these infections was not aggravated with denosumab. Somewhat surprising is the fact that 18% of the urine cultures were negative in the densoumab group, whereas there were no negative cultures in the control group. Thus, we cannot exclude that some of these clinically diagnosed episodes of urinary tract infection in the denosumab group were in fact abacterial, or caused by less traditional microorganisms. Nevertheless, the number of urinary tract infections was significantly higher in the denosumab group even after exclusion of the cases with negative culture. Thus, it is advisable to pay particular attention to the occurrence of urinary tract infections when denosumab is used early after renal transplantation, particularly because these infections are one of the major causes of morbidity and rehospitalization after kidney transplantation.
The incidence of pyelonephritis and urosepsis in the first year after kidney transplantation can be as high as 9% to 14% and 3% to 7%, respectively. [28] [29] [30] [31] As mentioned, the rate of pyelonephritis and urosepsis was comparable in both study arms, with 3 episodes (6.5%) in the denosumab group and 5 episodes (11.4%) in the control group. The routine use of antibiotic prophylaxis with trimethoprim-sulfamethoxazole in the first 6 months posttransplant may have prevented a higher incidence of more severe urinary tract infections, as it has been shown in other studies. 32 Of note, in patients with urinary tract infection the spectrum of urine bacteria was similar in the denosumab and the control group. E. coli, K. pneumoniae, and E. faecalis represented the most common infectious agents, as it is seen in the general transplant population. 33, 34 Because only 4 patients in the denosumab group and 3 patients in the control group had diabetes, we could not make a firm statement regarding the known association between diabetes mellitus and urinary tract infections.
CMV infection is the most common opportunistic infection in kidney transplant patients, occurring in approximately 8% of recipients. 35 Risk factors associated with CMV infection include the use of T cell-depleting antibodies, the presence of rejection, concurrent infections, and donor seropositivity. 36 In our study, the use of denosumab did not increase the incidence of CMV infection in the treatment group. Likewise, denosumab did not appear to increase the incidence and severity of BK viremia and BK nephropathy. Because all other infections occurred only in very low numbers of patients, no definitive conclusion regarding the influence of denosumab on these infections can be drawn. However, herpes zoster as well as skin and wound infections appeared to occur more commonly in denosumab-treated patients.
In conclusion, posttransplant treatment with denosumab to prevent bone loss is associated with more frequent episodes of urinary tract infection, whereas transplant-specific infections occurred with similar frequency in both groups. Caution regarding urinary tract infections and possibly wound, skin, and herpes zoster infections is advised when using denosumab early after renal transplantation when immunosuppression is at the highest level.
